20
Participants
Start Date
February 25, 2025
Primary Completion Date
October 29, 2027
Study Completion Date
October 31, 2028
Cyclophosphamide
Cyclophosphamide (Cy) is one part of the conditioning regimen. 50 mg/kg beginning on day -6.
Fludarabine
Fludarabine (Flu) is one part of the conditioning regimen. 150 mg/m2 (30 mg/m2 per day on days -6 to -2)
Thiotepa
Thiotepa (Thio) is one part of the conditioning regimen.10 mg/kg (5 mg/kg per day on days -5 and -4)
Total Body Irradiation
400 cGy (200 cGy per day on days -2 and -1).
Double Umbilical Cord Transplant
Cord blood is a regulated biologic. Selection of cord blood units will be based on published guidelines.
Tacrolimus
Tacrolimus will be administered post transplant. Graft-versus-host disease prophylaxis will consist of tacrolimus and mycophenolate mofetil (MMF), starting on day-5. Tacrolimus will continue at least until day 180 and then be tapered off.
Mycophenolate Mofetil
MMF will be administered post transplant. Graft-versus-host disease prophylaxis will consist of tacrolimus and mycophenolate mofetil (MMF), starting on day-5. MMF will continue until day 30.
Abatacept
Abatacept at a dose of 10mg/kg will be given on days T-1, T+5, T+14 and T+28.
RECRUITING
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
Leland Metheny
OTHER